Join Compugen for a virtual key opinion leader (KOL) event featuring Oladapo Yeku, MD, PhD, FACP (Harvard Medical School, Massachusetts General Hospital), who will join company management to discuss the evolving treatment landscape in ovarian cancer.

Dr. Yeku will preview the randomized MAIA-ovarian adaptive platform trial of COM701, a potential first-in-class anti-PVRIG antibody, evaluating safety and efficacy in the maintenance treatment of relapsed platinum sensitive ovarian cancer (PSOC), with median progression-free survival data from the interim analysis expected by Q1 2027.

Compugen’s Research and Discovery team will also provide an update on expanded capabilities of Unigen™, its AI-based target discovery platform, which enables the discovery of novel cancer immunotherapy drug targets and the continuous development of first-in-class drugs.

A live question and answer session will follow the formal presentations.